Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.

Familial cancer - 1 Jul 2022

Dettwyler Shenin A, Koeppe Erika S, Jacobs Michelle F, Stoffel Elena M

Abstract excerpt

Advances in cancer genetics have increased germline pathogenic/likely pathogenic variant (PV/LPV) detection rates. More data is needed to inform which patients with previously uninformative results could benefit most from retesting, especially beyond breast/ovarian cancer populations. Here, we describe retesting outcomes and predictors of PV/LPVs in a cohort of patients unselected by cancer diagnosis....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Genetic Predisposition to Disease
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34545504
DOI: 10.1007/s10689-021-00276-8
PMCID: PMC8934750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.PMID 34545504Read ↗

Outcomes of retesting BRCA negative patients using multigene panels.Semantic proximity Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling.Semantic proximity Read ↗

An analysis of the impact of annual cancer genetic testing guideline updates on a past patient population.Semantic proximity Read ↗

BRCA1/2 Variants Identified Through Tumor Genomic Profiling: Assessing Genetic Counseling Outcomes.Semantic proximity Read ↗

Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.Semantic proximity Read ↗

Germline Genetic Testing After Cancer DiagnosisSemantic proximity Read ↗

A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes.Semantic proximity Read ↗

Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.Semantic proximity Read ↗

Prevalence of Variant Reclassification Following Hereditary Cancer Genetic TestingSemantic proximity Read ↗

Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer.Semantic proximity Read ↗

Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.